Literature DB >> 1370774

Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen.

I S Misko1, C Schmidt, M Honeyman, T D Soszynski, T B Sculley, S R Burrows, D J Moss, K Burman.   

Abstract

There are two types, A and B, of Epstein-Barr virus (EBV) and B95-8 represents the common type A laboratory strain. Herein, we show in a family study that paternal EBV-specific cytotoxic T lymphocytes (CTL) generated in short-term cultures following stimulation with the autologous B95-8-transformed lymphoblastoid cell line (LCL) or B cells freshly infected with the B95-8 isolate did not lyse haploidentical B95-8 LCL expressing the HLA-A1, -B8, -DR3 paternal haplotype. In contrast, the haploidentical B95-8 LCL expressing the HLA-A11, -B51, -DR7 paternal haplotype was strongly lysed. Moreover, paternal CTL generated in response to stimulation with the B95-8 LCL expressing the haploidentical HLA-A1, -B8, -DR3 paternal haplotype included an allogeneic response against the maternal haplotype but no EBV-specific response as shown by the poor lysis of the autologous LCL target cells. However, stimulation with the haploidentical HLA-A11, -B51, -DR7 paternal haplotype resulted in the generation of both an allogeneic and an EBV-specific response. CTL clones were generated from two HLA-B8+ donors in response to stimulation with the autologous type A LCL transformed with wildtype EBV. The clones were cross-reactive for an immunodominant B95-8-associated peptide epitope that interacted with the HLA-B8 allele but failed to lyse B95-8-transformed LCL targets unless the targets were pre-coated with the exogenous peptide. A CTL clone that was initially stimulated with the autologous BL74 LCL lysed the spontaneous autologous LCL and spontaneous LCL from an HLA-B8+ donor, but failed to lyse the B95-8 LCL from that donor. The observed haplotype preference can be explained in terms of sequence variation between the B95-8 and the corresponding wildtype epitope. Our findings may help to clarify the role of EBV in the pathogenesis of primary Sjögren's syndrome which is closely associated with HLA-B8.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370774      PMCID: PMC1554241          DOI: 10.1111/j.1365-2249.1992.tb06414.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Authors:  S R Burrows; I S Misko; T B Sculley; C Schmidt; D J Moss
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  Detection of a second widespread strain of Epstein-Barr virus.

Authors:  J W Sixbey; P Shirley; P J Chesney; D M Buntin; L Resnick
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Primary Sjögren's syndrome after infectious mononucleosis.

Authors:  S Whittingham; J McNeilage; I R Mackay
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Factors influencing the human cytotoxic T cell response to autologous lymphoblastoid cell lines in vitro.

Authors:  I S Misko; T D Soszynski; R G Kane; J H Pope
Journal:  Clin Immunol Immunopathol       Date:  1984-09

7.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

8.  Long-term T-cell-mediated immunity to Epstein-Barr virus.

Authors:  A B Rickinson; D J Moss; L E Wallace; M Rowe; I S Misko; M A Epstein; J H Pope
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.

Authors:  M T Bejarano; M G Masucci; A Morgan; B Morein; G Klein; E Klein
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

10.  Murine cytotoxic T lymphocyte recognition of individual influenza virus proteins. High frequency of nonresponder MHC class I alleles.

Authors:  J R Bennink; J W Yewdell
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  3 in total

1.  Epstein-Barr virus and the lacrimal gland pathology of Sjögren's syndrome.

Authors:  S C Pflugfelder; C A Crouse; D Monroy; M Yen; M Rowe; S S Atherton
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

2.  Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.

Authors:  A B Hill; S P Lee; J S Haurum; N Murray; Q Y Yao; M Rowe; N Signoret; A B Rickinson; A J McMichael
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

3.  Analysis of cellular and humoral immune responses against cytomegalovirus in patients with autoimmune Addison's disease.

Authors:  Kine Edvardsen; Alexander Hellesen; Eystein S Husebye; Eirik Bratland
Journal:  J Transl Med       Date:  2016-03-09       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.